Treating COVID-19: Targeting the Host Response, Not the Virus

Area of Science:

• * Infectious Diseases
• * Pharmacology
• * Global Health

Background:

• * Severe COVID-19 poses a significant threat, particularly in low- and middle-income countries (LMICs).
• * Accessible and inexpensive generic medications are crucial for managing pandemics in resource-limited settings.
• * Existing generic drugs targeting host response, not the virus directly, could offer broad pandemic utility.

Purpose of the Study:

• * To evaluate the potential of inexpensive generic drugs, particularly in combination, for treating severe COVID-19 in LMICs.
• * To explore the feasibility of using readily available medications during global health crises.
• * To highlight the need for research into host-directed generic combination therapies for pandemic preparedness.

Main Methods:

• * Review of observational studies on inpatient statin use and mortality reduction.
• * Analysis of randomized controlled trials (RCTs) assessing statin efficacy.
• * Examination of combination treatment studies for antivirals and dexamethasone, contrasting with limited research on generic drug combinations.

Main Results:

• * Observational data suggest inpatient statin treatment may reduce 28-30 day mortality.
• * Randomized controlled trials have not consistently demonstrated this benefit for statins.
• * Combination generic drug treatments have been understudied, with limited evidence from observational studies.

Conclusions:

• * Inexpensive generic drug combinations targeting host response represent a promising, practical strategy for severe COVID-19 and future pandemics in LMICs.
• * Further research, including RCTs of combination generic drug therapies, is essential for pandemic preparedness.
• * The immediate availability of these drugs globally makes them a vital consideration for public health strategies.